Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) is developing Oncoprex
immunogene therapy as an innovative, gene therapy-based approach for the
treatment of non-small cell lung cancer (“NSCLC”). An article further
discussing the company reads, “NSCLC is the most common type of lung cancer. It
accounts for approximately 85% of all lung-cancer cases, and despite the
development of innovative treatment strategies, the survival rate for lung
cancer patients has not improved significantly over the past 25 years (http://ibn.fm/zQh71). . . .
Breakthrough technologies and therapeutic approaches like those developed by
Genprex could take cancer treatment solutions to a new level of effectiveness.
Gene therapy could be the one innovative development that will contribute to
curing what’s currently incurable, and companies like Genprex are spearheading
these efforts.”
To view the full article, visit http://ibn.fm/DCq7L
About Genprex Inc.
Genprex Inc. is a clinical-stage, gene-therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex immunogene therapy for non-small cell lung cancer.
Genprex’s platform technologies are designed to administer cancer-fighting
genes by encapsulating them into nanoscale hollow spheres called nanovesicles,
which are then administered intravenously and taken up by tumor cells where
they express proteins that are missing or found in low quantities. Oncoprex has
a multimodal mechanism of action whereby it interrupts cell-signaling pathways
that cause replication and proliferation of cancer cells; re-establishes
pathways for apoptosis, or programmed cell death, in cancer cell;, and
modulates the immune response against cancer cells. Oncoprex has also been
shown to block mechanisms that create drug resistance. For more information,
visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
